Pulmonx Corporation logo LUNG - Pulmonx Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 4
HOLD 4
SELL 1
STRONG
SELL 0
| PRICE TARGET: $10.00 DETAILS
HIGH: $20.00
LOW: $2.50
MEDIAN: $9.75
CONSENSUS: $10.00
UPSIDE: 740.69%

Stock News

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Jul 15, 2026 12:05 PM • globenewswire.com
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. , June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") to 17 individuals hired by Pulmonx in the first two quarters of 2026.

Jun 01, 2026 12:05 PM • globenewswire.com
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

Jun 01, 2026 12:05 PM • globenewswire.com
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Apr 15, 2026 12:05 PM • globenewswire.com
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Feb 20, 2026 03:00 AM • globenewswire.com
Reviewing Talkspace (NASDAQ:TALK) and Pulmonx (NASDAQ:LUNG)

Reviewing Talkspace (NASDAQ:TALK) and Pulmonx (NASDAQ:LUNG)

Talkspace (NASDAQ: TALK - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Talkspace and Pulmonx's net margins,

Feb 18, 2026 10:32 PM • defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison

SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison

SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Risk and Volatility SOPHiA GENETICS has a beta

Jan 31, 2026 08:10 PM • defenseworld.net
Pulmonx (NASDAQ:LUNG) & Alternate Health (OTCMKTS:AHGIF) Critical Comparison

Pulmonx (NASDAQ:LUNG) & Alternate Health (OTCMKTS:AHGIF) Critical Comparison

Alternate Health (OTCMKTS:AHGIF - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Valuation and Earnings This table compares Alternate Health and

Jan 22, 2026 09:48 PM • defenseworld.net

Price Targets